Clinical Trial Update: An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg [Phase 1]

View source ↗

Summary

An open-label Phase 1 study assessing dose proportionality of OROS Hydromorphone HCl Tablets across 8, 16, 32, and 64 mg to characterize pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Analgesia

Drugs mentioned

• OROS Hydromorphone HCl Tablets (hydromorphone hydrochloride)

Snippet

Sponsor: Alza Corporation, DE, USA | Conditions: Analgesia | Phase 1 | Status: COMPLETED